For the possible but so far not recognized BPC 157/NO-system connection, we indicated [171] that under the same L-NAME non-responsive/L-arginine responsive paradigm, this counteraction of resembling negative-like symptoms (cognitive dysfunction) [204,205,206,207] completely corresponded to the counteraction of the similar positive-like symptoms [200] (acute apomorphine, chronic methamphetamine, and acute MK-801 induced effects and acute haloperidol induced catalepsy) [208,209,210,211,212,213,214,215]
The reason why is so easy to see: current data suggest that many if not most people currently taking a GLP-1 will not be on it forever
A GLP-1 tracker only proves its value on the weeks when your routine breaks: travel, refill stress, poor sleep, appetite swings, and a short doctor visit coming up
So happy I found them
Images such as these encapsulate treatment outcomes in a simple format that is easy to understand, even for people not familiar with the nuances of scientific publications